Adaptive Biotechnologies Corporation
Seattle, Washington, United States · Biotechnology, Health Care, Therapeutics
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system's biology to transform disease diagnosis and treatment. They develop clinical products aimed at diagnosing and treating diseases using advanced genetic techniques. Their flagship product, clonoSEQ®, is designed to detect minimal residual disease in various blood cancers. The compan
Key facts
- Headquarters
- Seattle, Washington, United States
- Employees
- 670
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (ADPT)
- Website
- adaptivebiotech.com
- Company page
Recent activity at Adaptive Biotechnologies Corporation
- : Adaptive raises $30 million in Series B funding led by Tidemark to enhance its agentic accounting platform for construction.
- : Adaptive has secured a strategic investment from Citi and HSBC to boost its product innovation and cloud-native solutions.
- : SEC 8-K (8.01): On December 30, 2025, Adaptive Biotechnologies Corporation announced that its 70% owned subsidiary, Digital Biotechnologies, Inc., achieved an initial closing of its Series A Preferred Stock financing, with expected total proceeds of up to $15 million. Following the completion of this financing round, Adaptive anticipates retaining nearly a 50% ownership interest in Digital Biotechnologies. This event is significant as it will allow Adaptive Biotechnologies to continue consolidating the subsidiary's results in its financial statements, indicating a strategic move to strengthen its position in the biotechnology market amidst financial growth potential.
- : Adaptive Biotechnologies and Pfizer enter two significant partnerships worth up to $890 million for T-cell receptor research and AI drug discovery.
- : Adaptive, a San Francisco startup, raised $7M in Seed funding led by Pebblebed to expand operations and development efforts.
- : Adaptive and Rapid Addition Announce Partnership for Best-in-class FIX Capabilities
- : Adaptive Biotechnologies Corporation presents clonoSEQ® MRD Testing at the 66th ASH Annual Meeting to showcase its effectiveness in blood cancer treatment.
- : Adaptive closes $19M Series A to transform construction finance with AI and automation
- : Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Million
Adaptive Biotechnologies Corporation funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Series B | $30.0M |
| Mar 2026 | Corporate Round | Undisclosed |
| Apr 2025 | Seed | $7.0M |
| Jul 2024 | Series A | $19.0M |
| Sep 2022 | Grant | Undisclosed |
Leadership
- Chad Robins, CEO
- Tycho Peterson, CFO
- Francis Lo, Chief People Officer
- Chad Robins, Chief Executive Officer
- Alejandra Gonzalez, Adaptive Hr Director
- Sarah Kinney, Hr Professional With Sphr
- Jeanne Schreuder, Mba, Sphr
- Kyle Piskel, Not Specified
- Ashley Derezes, CPA
- Richard Chaplin, Finance Professional With 30+ Years
- Chris Youmans, Strategic Technology Leader
- Jack Dempsey, Applications Development and Data Engineering
Verified email and direct lines for Adaptive Biotechnologies Corporation’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Adaptive Biotechnologies Corporation files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Adaptive Biotechnologies Corporation in the news
- Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering - GlobeNewswire (Jun 15, 2026)
- Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ® - GlobeNewswire (Sep 17, 2026)
- Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering - GlobeNewswire (Jun 17, 2026)
- What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors? - Yahoo Finance (Jun 14, 2026)
- Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science - GeekWire (Aug 17, 2026)
- Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses - GlobeNewswire (Jun 15, 2026)
- Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing - Microsoft Source (May 05, 2020)
- Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026 - Yahoo Finance (Jun 03, 2026)
Companies similar to Adaptive Biotechnologies Corporation
- Cytokinetics · Biotechnology, Health Care, Therapeutics
- Madrigal Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Apellis Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Arcus Biosciences · Biotechnology, Health Care, Therapeutics
- BridgeBio · Biotechnology, Health Care, Therapeutics
About Adaptive Biotechnologies Corporation: questions and answers
What does Adaptive Biotechnologies Corporation do?
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system's biology to transform disease diagnosis and treatment. They develop clinical products aimed at diagnosing and treating diseases using advanced genetic techniques. Their flagship product, clonoSEQ®, is designed to detect minimal residual disease in various blood cancers. The compan
Where is Adaptive Biotechnologies Corporation headquartered?
Adaptive Biotechnologies Corporation is headquartered in Seattle, Washington, United States.
How many employees does Adaptive Biotechnologies Corporation have?
Adaptive Biotechnologies Corporation has about 670 employees.
Has Adaptive Biotechnologies Corporation raised funding?
Yes. Fundz has recorded 5 funding events for Adaptive Biotechnologies Corporation. The most recent, Series B of $30.0M, was in Sep 2026.
Who leads Adaptive Biotechnologies Corporation?
Chad Robins is a CEO at Adaptive Biotechnologies Corporation.
What is the latest news on Adaptive Biotechnologies Corporation?
On Sep 17, 2026, Adaptive raises $30 million in Series B funding led by Tidemark to enhance its agentic accounting platform for construction.
Is Adaptive Biotechnologies Corporation a public company?
Yes. Adaptive Biotechnologies Corporation is publicly traded under the ticker ADPT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy